How Does Low-Dose Naltrexone Work?

Low-dose naltrexone works through at least two distinct pharmacological pathways that have nothing to do with what naltrexone does at its standard dose. At full strength (50 to 150 mg), naltrexone blocks opioid receptors around the clock and is prescribed for alcohol and opioid use disorders. But at roughly one-tenth that dose, typically 1 to 5 mg taken at bedtime, the drug’s blockade is brief enough to trigger a rebound effect in the body’s own opioid system while separately acting on immune cells to dial down inflammation. These two mechanisms, and a third involving cell growth regulation, explain why LDN keeps turning up in research on conditions as different as Crohn’s disease, fibromyalgia, and long COVID.

The Endorphin Rebound

The most widely discussed explanation for how LDN works centers on what happens after the drug wears off. At a low dose, naltrexone occupies opioid receptors for only a few hours rather than the full day that a standard dose would. The body senses this brief blockade and compensates by producing more endogenous opioids, including beta-endorphin, and by increasing the number of opioid receptors on cell surfaces. This compensatory upregulation has been demonstrated repeatedly in animal studies and is sometimes called the “opioid rebound effect.”¹

Why would higher endorphin levels matter for someone with an autoimmune or inflammatory condition? Beta-endorphin does more than dull pain. It helps regulate the balance of inflammatory signaling molecules in the body and feeds into the opioid growth factor pathway, which influences how immune cells behave and how tissues repair themselves.² The timing matters: LDN is typically taken before bed so that the blockade happens overnight and the rebound in endorphin production unfolds during sleep and into the following day. If you took enough naltrexone to block receptors around the clock, the rebound would never get a chance to kick in, which is why the “low dose” part of LDN is not just about reducing side effects but is fundamental to the mechanism.

Turning Down Neuroinflammation Through TLR4

A second mechanism operates entirely outside the opioid receptor system. Naltrexone, even in small amounts, binds to a receptor on immune cells called Toll-like receptor 4, or TLR4. TLR4 is found on microglia, the brain’s resident immune cells, and on other immune cells throughout the body. When TLR4 is activated, it triggers a cascade of inflammatory signaling. Naltrexone acts as an antagonist at TLR4, essentially blocking this activation and reducing the release of pro-inflammatory molecules downstream.³

Research on this pathway has shown that naltrexone can shift microglia from a highly activated, pro-inflammatory state to a quieter, anti-inflammatory state. In lab studies, naltrexone reversed the metabolic reprogramming that immune cells undergo when they become hyperactive, pushing them back from a high-energy inflammatory mode toward a calmer baseline.⁴ Computational modeling has further clarified that naltrexone docks into the same binding pocket on TLR4’s accessory protein that bacterial toxins use, physically blocking inflammatory signals from getting through.⁵

This TLR4 mechanism helps explain why LDN has shown effects on neuropathic pain, where overactive microglia are a known driver. It also suggests the drug is doing something genuinely anti-inflammatory rather than merely masking pain signals, which is a different proposition from most painkillers.

The Opioid Growth Factor Pathway

A third mechanism involves a peptide called opioid growth factor, or OGF, which is actually the endogenous enkephalin met-enkephalin. OGF and its receptor, OGFr, regulate how fast cells divide. When OGF binds OGFr, it puts the brakes on cell proliferation. LDN temporarily blocks OGFr, and the body compensates by producing more OGF. Once the brief blockade wears off, the now-elevated OGF levels exert a stronger-than-normal inhibitory effect on cell growth.⁶

This pathway is particularly relevant to autoimmune diseases, where immune cells proliferate out of control, and to cancer, where tumor cells do the same. In mouse models of multiple sclerosis, for example, LDN restored depleted enkephalin levels and reduced both the behavioral and tissue-level signs of disease. The pattern is the same across conditions: brief receptor blockade, compensatory rise in the natural growth-regulating peptide, and a net suppressive effect on runaway cell division.

What Clinical Trials Have Found So Far

The mechanistic picture is compelling, but clinical trial results have been decidedly mixed, and this is the honest state of the evidence. LDN research is plagued by small sample sizes, inconsistent dosing, and a near-total absence of industry funding, since naltrexone is a generic drug with no patent protection left to motivate large trials.

The strongest positive signal comes from Crohn’s disease. In a randomized, placebo-controlled trial, 88% of patients receiving LDN had a clinically meaningful drop in disease activity scores, compared to 40% on placebo. Perhaps more striking, 78% of the LDN group showed visible healing of the intestinal lining on endoscopy, compared to 28% on placebo, and about a third achieved endoscopic remission.⁷ That endoscopic result is harder to attribute to placebo effects, since physical healing of intestinal tissue is an objective measurement.

Fibromyalgia has drawn the most attention and also the most disappointing headline result. The largest trial to date, a well-designed randomized controlled trial published in The Lancet Rheumatology, tested 6 mg of LDN in women with fibromyalgia and found no statistically significant difference from placebo in pain reduction. The LDN group’s pain dropped by about 1.3 points on a standard scale, while the placebo group dropped by 0.9 points, a gap that could easily be random noise.⁸ Earlier, smaller studies had been more optimistic, which is a common pattern in medicine: small pilot studies look promising, then larger rigorous trials temper the excitement.

Multiple sclerosis research shows a similar split. One pilot trial found that LDN significantly improved mental health quality-of-life measures in MS patients, including mood, perceived cognitive deficits, and the impact of pain on daily life.⁹ But a separate randomized placebo-controlled trial found no meaningful differences between LDN and placebo across measures of pain, energy, emotional well-being, cognition, and sexual function.¹⁰ The picture is not “LDN clearly works for MS.” It is “some measures improved in some studies and not in others, and the trials have been too small to settle the question.”

Long COVID and Persistent Fatigue

LDN has recently attracted interest as a treatment for the fatigue and cognitive symptoms that linger after COVID-19. A systematic review and meta-analysis of the available studies found statistically significant improvements in fatigue, brain fog, and headaches among people taking LDN for long COVID.¹¹ The review’s authors were careful to note that the underlying studies were mostly observational or uncontrolled, so the evidence is preliminary at best.

One pilot study treated 36 patients who had persistent moderate-to-severe fatigue after COVID with a combination of LDN at 4.5 mg daily plus NAD+ supplementation. After 12 weeks, quality-of-life scores improved significantly and fatigue ratings dropped substantially. About half the patients qualified as responders. The combination design makes it impossible to tease apart how much credit LDN deserves versus the NAD+ supplementation, and there was no placebo group.¹² Still, the rationale makes sense given the neuroinflammatory and immune-dysregulation theories of long COVID: if LDN calms overactive microglia and restores endorphin balance, it could plausibly address some of the brain fog and fatigue that characterize the condition.

Skin Conditions

One of the more surprising areas where LDN has shown up is dermatology. A systematic review in JAMA Dermatology found evidence that LDN was safe and effective for Hailey-Hailey disease, a chronic blistering skin condition, and for lichen planopilaris, a form of scarring hair loss. Both low-dose and standard-dose naltrexone also reduced itching from various causes, though higher doses came with more side effects.¹³

The list of skin conditions where LDN has been tried keeps growing. A 2025 clinical review catalogued evidence for LDN in psoriasis, Darier disease, dermatomyositis, hidradenitis suppurativa, and even body-focused repetitive behaviors like skin picking, with improvements reported in disease severity, affected body surface area, and symptom burden.¹⁴ Most of this evidence comes from case series and small uncontrolled studies, so the excitement is warranted only with caution. But for skin conditions that have few effective treatments, even case-series evidence can be meaningful to patients and dermatologists looking for options.

Preclinical Cancer Research

LDN’s ability to regulate the opioid growth factor pathway has led to research in oncology, though almost entirely in animal models and cell cultures so far. In mice with ovarian cancer, LDN significantly reduced tumor burden by inhibiting tumor cell proliferation and the growth of new blood vessels feeding the tumors.¹⁵ In colorectal cancer models, LDN appeared to shift immune cells within the tumor environment toward a more anti-tumor state and triggered cancer cell death through a well-characterized apoptosis pathway.¹⁶

The appeal of LDN as a potential cancer adjuvant is that it does not directly kill cells the way chemotherapy does. It works indirectly, by boosting the body’s own growth-regulating peptides and by nudging the immune environment in a direction less hospitable to tumors.¹⁷ In theory, this means LDN could be layered on top of conventional treatments without adding toxicity. In practice, there are no published randomized controlled trials of LDN in human cancer patients, so this remains a hypothesis supported by animal data rather than clinical evidence.

Side Effects and Safety

The safety profile of LDN is one of its most frequently cited advantages, and the evidence backs this up. Across the available literature, adverse effects are generally described as minimal to mild. The most commonly reported side effects are vivid dreams, diarrhea, and headaches.¹⁸

The vivid dreams deserve specific mention because they are strikingly consistent across studies. A meta-analysis of fibromyalgia trials found that patients taking LDN were about two and a half times more likely to report vivid dreams than those on placebo.¹⁹ Most people who experience them describe the dreams as unusual or intense rather than distressing, and for many the effect fades after the first few weeks. Some clinicians advise patients to take LDN in the morning instead of at bedtime if dream disturbances become bothersome, though this may slightly alter the timing of the endorphin rebound.

Because standard-dose naltrexone carries a boxed warning for liver toxicity at high doses, patients sometimes worry about liver damage from LDN. At doses of 1 to 5 mg, there is no evidence of hepatotoxicity in the published literature. The concern applies to the 50 to 150 mg range used in addiction medicine, not to the doses used in LDN protocols.

The Opioid Interaction You Should Know About

There is one safety issue that deserves more attention than it usually gets. Because LDN upregulates opioid receptors, patients who are taking or may need opioid medications face a real risk of hypersensitivity. A case report describes a patient on LDN for multiple sclerosis who received a single 5 mg dose of oxycodone and became profoundly sedated, unresponsive to painful stimuli, requiring multiple doses of naloxone and an overnight stay in intensive care.²⁰

The problem is that standard drug interaction databases flag the combination of naltrexone and opioids as a risk of opioid withdrawal, which is the correct concern at standard naltrexone doses. But at low doses, the interaction works in the opposite direction: LDN makes you more sensitive to opioids, not less. A dose that would normally produce mild pain relief can instead cause dangerous respiratory depression. Anyone taking LDN should make sure their doctors, including emergency physicians who might prescribe opioids after an injury or surgery, know about it. Wearing a medical alert bracelet or carrying a wallet card is not an overreaction.

Ultra-Low-Dose Is a Different Drug

You may encounter references to “ultra-low-dose naltrexone,” and it is worth knowing that this is a pharmacologically distinct concept from LDN. Ultra-low-dose naltrexone involves doses of less than one microgram per day, roughly a thousand times smaller than a typical LDN dose. At this ultra-low range, naltrexone works through a completely different target: a scaffolding protein called filamin A that is involved in opioid receptor signaling. The effect is to enhance opioid pain relief rather than to trigger an endorphin rebound or calm inflammation.²¹ Ultra-low-dose naltrexone is sometimes combined with opioid prescriptions to improve analgesia and reduce tolerance, which is essentially the opposite of what LDN does. Confusing the two is easy and potentially dangerous, since the doses differ by several orders of magnitude and the clinical goals are contradictory.

Why LDN Is Hard to Get and Hard to Study

Naltrexone is FDA-approved only in 50 mg tablets and a monthly injectable formulation, both intended for addiction treatment. No pharmaceutical company has sought approval for a low-dose indication, because the drug is generic and there is no financial incentive to fund the large clinical trials that approval would require. As a result, LDN is almost always obtained from compounding pharmacies, which prepare custom doses based on a physician’s prescription.

This creates a research bottleneck. Without industry sponsorship, trials depend on academic grants, which tend to be small. The largest fibromyalgia trial that failed to beat placebo enrolled only about 100 patients. For comparison, pivotal drug-approval trials routinely enroll thousands. The absence of standardized formulations also means that the LDN used in one study may differ in absorption characteristics from the LDN used in another, since compounding pharmacies can use different fillers and preparation methods. Until someone funds larger, multi-center trials with standardized compounded products, the evidence base will remain a patchwork of small studies with mixed results.

For patients and clinicians trying to interpret the current evidence, the practical takeaway is that LDN’s mechanisms are biologically plausible and well-supported by lab research, but the clinical proof is thin for most conditions. Crohn’s disease has the most encouraging trial data. Fibromyalgia, despite being one of the most common off-label uses, has the most discouraging flagship trial. Long COVID is too new and under-studied to draw firm conclusions. And the oncology research, while fascinating, is still confined to mice and petri dishes. The drug’s excellent safety profile means the risk of trying it is low, but “low risk” should not be confused with “proven benefit.”